All of this work has sparked entrepreneurial interest. The Harvard spinout Elevian, for example, led by entrepreneur Dr. Mark Allen and a quartet of the school’s regenerative biology professors, is seeking longevity in GDF11 and similar age-retardant molecules. The Stanford spinout Alkahest, meanwhile, is searching for an optimized plasma cocktail as a treatment for Alzheimer’s.
